Study lung cancer biology and why immunotherapy stops working
Part of Cancer, Lungs & breathing clinical trials.
This study looks at lung cancer tissue and immune system changes to understand how and why immunotherapy resistance develops. It may help researchers find better ways to make immunotherapy work longer for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of lung cancer from pathology or blood tests
- You have never received any anti-cancer treatment before starting the study
- You do not have another active cancer at the same time or within the past 5 years
- You have not joined another treatment study and received research drugs or devices in the last 4 weeks
- You do not have an active autoimmune disease needing whole-body treatment in the last 2 years
- You have not taken whole-body immune-suppressing medicines or steroid tablets in the last 7 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
This study looks at preserved tissue samples from people with lung cancer to understand why some tumors don't respond to immunotherapy drugs like PD-1/PD-L1 inhibitors. The goal is to find patterns that could help predict treatment success.
This study looks at genetic information from tumor tissue of people with non-small cell lung cancer who had immunotherapy before surgery but still had some cancer cells left. The goal is to understand why the cancer did not completely respond to treatment.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.